Design Therapeutics DSGN Stock
Design Therapeutics Price Chart
Design Therapeutics DSGN Financial and Trading Overview
Design Therapeutics stock price | 3.61 USD |
Previous Close | 5.4 USD |
Open | 5.4 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 800 |
Day's Range | 5.4 - 5.63 USD |
52 Week Range | 4.9 - 26.3 USD |
Volume | 240.93K USD |
Avg. Volume | 329.79K USD |
Market Cap | 306.58M USD |
Beta (5Y Monthly) | 1.204194 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.88 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.4 USD |
DSGN Valuation Measures
Enterprise Value | -9890371 USD |
Trailing P/E | N/A |
Forward P/E | -2.9462366 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.97962105 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | 0.131 |
Trading Information
Design Therapeutics Stock Price History
Beta (5Y Monthly) | 1.204194 |
52-Week Change | -61.16% |
S&P500 52-Week Change | 20.43% |
52 Week High | 26.3 USD |
52 Week Low | 4.9 USD |
50-Day Moving Average | 6.2 USD |
200-Day Moving Average | 10.48 USD |
DSGN Share Statistics
Avg. Volume (3 month) | 329.79K USD |
Avg. Daily Volume (10-Days) | 209.12K USD |
Shares Outstanding | 55.95M |
Float | 11.43M |
Short Ratio | 34.05 |
% Held by Insiders | 36.97% |
% Held by Institutions | 73.68% |
Shares Short | 7.11M |
Short % of Float | 21.16% |
Short % of Shares Outstanding | 12.70% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -13.48% |
Return on Equity (ttm) | -20.30% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -48613000 USD |
EBITDA | -75421000 USD |
Net Income Avi to Common (ttm) | -69337000 USD |
Diluted EPS (ttm) | -1.21 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 315.39M USD |
Total Cash Per Share (mrq) | 5.64 USD |
Total Debt (mrq) | 3.54M USD |
Total Debt/Equity (mrq) | 1.13 USD |
Current Ratio (mrq) | 35.254 |
Book Value Per Share (mrq) | 5.594 |
Cash Flow Statement
Operating Cash Flow (ttm) | -56914000 USD |
Levered Free Cash Flow (ttm) | -33390250 USD |
Profile of Design Therapeutics
Country | United States |
State | CA |
City | Carlsbad |
Address | 6005 Hidden Valley Road |
ZIP | 92011 |
Phone | 858 293 4900 |
Website | https://www.designtx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 64 |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Q&A For Design Therapeutics Stock
What is a current DSGN stock price?
Design Therapeutics DSGN stock price today per share is 3.61 USD.
How to purchase Design Therapeutics stock?
You can buy DSGN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Design Therapeutics?
The stock symbol or ticker of Design Therapeutics is DSGN.
Which industry does the Design Therapeutics company belong to?
The Design Therapeutics industry is Biotechnology.
How many shares does Design Therapeutics have in circulation?
The max supply of Design Therapeutics shares is 56.76M.
What is Design Therapeutics Price to Earnings Ratio (PE Ratio)?
Design Therapeutics PE Ratio is now.
What was Design Therapeutics earnings per share over the trailing 12 months (TTM)?
Design Therapeutics EPS is -0.88 USD over the trailing 12 months.
Which sector does the Design Therapeutics company belong to?
The Design Therapeutics sector is Healthcare.
Design Therapeutics DSGN included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 17449.89 USD — |
+0.87
|
6.97B USD — | 17149.36 USD — | 17506.58 USD — | — - | 6.97B USD — |
Stlmt ID NASDAQ Biotechnology NBX | 4486.38 USD — |
-0.37
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 8541.08 USD — |
+0.91
|
— — | 8392.44 USD — | 8567.09 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4132.89 USD — |
-2.63
|
— — | 4122.19 USD — | 4247.3 USD — | — - | — — |
NASDAQ HealthCare IXHC | 929.13 USD — |
-1.85
|
— — | 925.14 USD — | 947.12 USD — | — - | — — |
- {{ link.label }} {{link}}